ePrints

UK national survey of anticoagulation in extra-corporeal photopheresis—Is it time for a UK consensus statement?

Lookup NU author(s): Professor Andrew GenneryORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2021 British Blood Transfusion Society. Background: Extra-corporeal photopheresis (ECP) requires anticoagulation to prevent circuit clotting. Unfractionated heparin (UFH) is currently the only anticoagulant licensed for the ECP system in use in the United Kingdom (UK). Acid citrate dextrose-A (ACD-A) is the preferred anticoagulant for most other apheresis procedures. Anecdotal evidence suggested variability in ECP practice across the UK with some providers using off-label ACD-A. Aims: We developed a survey together with the UK Photopheresis Society to establish current practice. Materials & Methods: This was distributed to all 17 ECP providers covering 34 UK sites. Results: Significant variability in practice was demonstrated with only 36% of responding providers (5/14) using UFH exclusively and 29% (4/14) using ACD-A as standard. Conclusion: This survey highlights the need for a UK consensus.

Publication metadata

Author(s): Wolf J, Alfred A, Gennery AR, New HV, Scarisbrick J, Griffin J

Publication type: Article

Publication status: Published

Journal: Transfusion Medicine

Year: 2022

Volume: 32

Issue: 1

Pages: 77-81

Print publication date: 01/02/2022

Online publication date: 02/12/2021

Acceptance date: 04/11/2021

ISSN (print): 0958-7578

ISSN (electronic): 1365-3148

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1111/tme.12836

DOI: 10.1111/tme.12836

Altmetrics

Share